Physician profile
Christopher Gerald Schrepferman
NPI 1316030612
$5,297.83
in general payments reported to CMS, 2019-2025
34 companies · $899 in 2025
The $899 reported for 2025 was more than what a typical Urology provider received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $514 · 2020: $405 · 2021: $364 · 2022: $1,360 · 2023: $1,130 · 2024: $624 · 2025: $899.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,616 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $38.48.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,615.62 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $38.48 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $1,588.55 | 2021-2025 | Interstim, Altaviva |
| Medtronic USA, INC. | $615.19 | 2019-2020 | |
| Procept Biorobotics Corporation | $358.25 | 2021-2024 | Aquabeam Robotic System, Aquabeam System |
| Teleflex LLC | $337.47 | 2022-2023 | Urolift |
| Urogen Pharma, INC. | $235.34 | 2021-2025 | |
| Boston Scientific Corporation | $212.32 | 2019-2025 | General - Kidney Stone Disease, Rezum Generator |
| Myriad Genetic Laboratories, INC. | $178.53 | 2022-2024 | Prolaris |
| Halozyme INC | $170.62 | 2023 | |
| Blue Earth Diagnostics | $158.37 | 2020-2025 | Posluma |
| Antares Pharma, INC. | $153.84 | 2020-2025 | Xyosted |
| Astellas Pharma US INC | $144.80 | 2019-2023 | Myrbetriq |
| Accord Healthcare, INC. | $125.09 | 2022-2025 | |
| Sanara Medtech INC. | $122.85 | 2022 | |
| Abbvie INC. | $117.69 | 2022-2025 | Botox |
| Calyxo, INC. | $97.93 | 2025 | Cvac Aspiration System |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Endo Pharmaceuticals INC. | $72.61 | 2021 | |
| Axonics, INC. | $65.11 | 2022-2023 | Axonics |
| E.R. Squibb & Sons, L.L.C. | $64.00 | 2022-2023 | |
| Sumitomo Pharma America, INC. | $53.58 | 2023-2024 | Orgovyx, Gemtesa |
| Merck Sharp & Dohme LLC | $50.77 | 2020-2024 | Welireg, Keytruda |
| Verity Pharmaceuticals INC. | $50.49 | 2022-2025 | Tlando |
| Myovant Sciences INC. | $49.11 | 2022 | |
| Bioprotect Medical, INC. | $47.10 | 2024 | Bioprotect Balloon Implant System |
| Siemens Medical Solutions USA, INC. | $38.88 | 2021 | |
| Urovant Sciences INC | $31.60 | 2022 | |
| Pfizer INC. | $29.49 | 2020-2022 | |
| Neotract INC. | $27.31 | 2019 | |
| Therapeuticsmd, INC. | $20.60 | 2019 | |
| Tolmar Pharmaceuticals, INC. | $19.07 | 2022 | |
| Ferring Pharmaceuticals INC. | $18.81 | 2025 | Adstiladrin |
| Clarus Therapeutics INC. | $17.87 | 2021 | |
| Amgen INC. | $13.49 | 2020 | |
| Zyla Life Sciences, INC. | $11.10 | 2020 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$9,770.18 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Schrepferman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.